Results 231 to 240 of about 2,204,237 (310)

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi   +28 more
wiley   +1 more source

Tissue-resident memory CD8+T cells might enhance HBV DNA clearance in CHB patients with MASLD complication and normal ALT via the CCL-CCR pathways. [PDF]

open access: yesFront Cell Infect Microbiol
Cai C   +16 more
europepmc   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

open access: yesHepatology Research, Volume 56, Issue 2, Page 246-252, February 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda   +11 more
wiley   +1 more source

Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors. [PDF]

open access: yesTher Adv Med Oncol
Qin Q   +11 more
europepmc   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

open access: yesHIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano   +6 more
wiley   +1 more source

The Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable HBV-DNA under NA Therapy: A Multicenter Study. [PDF]

open access: yesIntern Med
Amano K   +10 more
europepmc   +1 more source

KLF1 Exerts Pro‐Tumour Role in Liver Cancer via Inhibiting ACSL4/LPCAT3‐Regulated Ferroptosis

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Kruppel‐like factors (KLFs) constitute a crucial family of transcription factors that are engaged in a variety of biological processes, such as erythropoiesis as well as liver development. A growing body of research underscores the increasing importance of the KLF family in the context of hepatocellular carcinoma (HCC). Despite this, the exact
Zhihui Chen   +3 more
wiley   +1 more source

Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment. [PDF]

open access: yesJ Clin Invest
Taddese M   +15 more
europepmc   +1 more source

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy